Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects

Published:2017-05 Issue: Volume:32 Page:1-15
ISSN:1368-7646
Container-title:Drug Resistance Updates
language:en
Short-container-title:Drug Resistance Updates

Author:

Jia Hongyan,Truica Cristina I.,Wang Bin,Wang Yanhong,Ren Xingcong,Harvey Harold A.,Song Jianxun,Yang Jin-Ming

Funder

National Natural Science Foundation of China

First Hospital of Shanxi Medical University

Publisher

Elsevier BV

Subject

Pharmacology (medical),Infectious Diseases,Cancer Research,Pharmacology,Oncology

Reference151 articles.

1. NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer;Ademuyiwa;PLoS One,2012

2. A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients;Alfonso;Clin. Cancer Res.,2014

3. The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases;Anders;Cancer,2011

4. The evolution of triple-Negative Breast cancer: from biology to novel therapeutics;Anders;Am. Soc. Clin. Oncol. Educ. Book Am. Soc. Clin. Oncol. Meet.,2016

5. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial;Armand;J. Clin. Oncol.,2013

Cited by 142 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enhanced drug delivery with nanocarriers: a comprehensive review of recent advances in breast cancer detection and treatment;Discover Nano;2024-09-07

2. An immunoinformatics approach for a potential NY-ESO-1 and WT1 based multi-epitope vaccine designing against triple-negative breast cancer;Heliyon;2024-09

3. Targeting Metabolic–Redox Nexus to Regulate Drug Resistance: From Mechanism to Tumor Therapy;Antioxidants;2024-07-10

4. The therapeutic role of γδT cells in TNBC;Frontiers in Immunology;2024-06-12

5. Immunotherapeutic Strategies Targeting Breast Cancer Stem Cells;Current Oncology;2024-05-29

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3